Jiaqi Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiaqi Yu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Chongming Wu
School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China
2 shared publications Hongju Xiang
Department of Cardiovascular Medicine, Xiangxi Tujia and Miao Autonomous Prefecture People’s Hospital, The First Affiliated Hospital of Jishou University
2 shared publicationsLiping Du
Medical College of Jishou University
2 shared publicationsXiangyong Hu
Department of Cardiovascular Medicine, Xiangxi Tujia and Miao Autonomous Prefecture People’s Hospital, The First Affiliated Hospital of Jishou University
2 shared publicationsZhixiong Liao
Department of Cardiovascular Medicine, Zhangjiajie People’s Hospital, Jishou University
2 shared publications- Dong Liu
State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
1 shared publication
Latest Publications
- Open Access
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 14, 1751640
A biohybrid nanovesicle hijacks inflammatory chemotaxis to deliver colchicine for myocardial infarction therapy
Introduction: Myocardial infarction (MI) triggers an excessive inflammatory response that drives adverse cardiac remodeling. Although colchicine has shown clinical promise, its narrow therapeutic window and lack of target specificity limit its efficacy. To address these limitations, we developed a biohybrid nanovesicle (MM‐LP@COL) that encapsulates colchicine, aiming to leverage natural inflammatory tropism for site-specific drug delivery. Methods: MM‐LP@COL nanovesicles were fabricated by fusing macrophage membranes with liposomes. Physicochemical characterization was performed using DLS, TEM, and FRET analysis. Cytokine‐scavenging capacity was evaluated in vitro by ELISA. In a murine MI model, mice were treated with PBS, free colchicine, LP@COL, or MM‐LP@COL. Immune cell populations in blood, bone marrow, and spleen were analyzed by high‐dimensional flow cytometry (UMAP). Cardiac function and tissue remodeling were assessed by echocardiography and histology. Results: MM‐LP@COL formed uniform spherical nanovesicles (∼200 nm) and demonstrated potent, dose‐dependent neutralization of multiple pro‐inflammatory cytokines in vitro , along with reduced circulating cytokine levels in MI mice. High‐dimensional cytometric analysis revealed that treatment significantly reduced neutrophil infiltration across key immune organs, including blood, bone marrow, and spleen. These effects translated into improved left ventricular function, reduced myocardial inflammation, and attenuated cardiomyocyte hypertrophy. Discussion: This study demonstrates that the macrophage-inspired nanovesicle system constitutes a potent and targeted combinatorial therapy for post-infarction inflammation and repair.
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 14, 1751640
Open AccessA biohybrid nanovesicle hijacks inflammatory chemotaxis to deliver colchicine for myocardial infarction therapy
Introduction: Myocardial infarction (MI) triggers an excessive inflammatory response that drives adverse cardiac remodeling. Although colchicine has shown clinical promise, its narrow therapeutic window and lack of target specificity limit its efficacy. To address these limitations, we developed a biohybrid nanovesicle (MM‐LP@COL) that encapsulates colchicine, aiming to leverage natural inflammatory tropism for site-specific drug delivery. Methods: MM‐LP@COL nanovesicles were fabricated by fusing macrophage membranes with liposomes. Physicochemical characterization was performed using DLS, TEM, and FRET analysis. Cytokine‐scavenging capacity was evaluated in vitro by ELISA. In a murine MI model, mice were treated with PBS, free colchicine, LP@COL, or MM‐LP@COL. Immune cell populations in blood, bone marrow, and spleen were analyzed by high‐dimensional flow cytometry (UMAP). Cardiac function and tissue remodeling were assessed by echocardiography and histology. Results: MM‐LP@COL formed uniform spherical nanovesicles (∼200 nm) and demonstrated potent, dose‐dependent neutralization of multiple pro‐inflammatory cytokines in vitro , along with reduced circulating cytokine levels in MI mice. High‐dimensional cytometric analysis revealed that treatment significantly reduced neutrophil infiltration across key immune organs, including blood, bone marrow, and spleen. These effects translated into improved left ventricular function, reduced myocardial inflammation, and attenuated cardiomyocyte hypertrophy. Discussion: This study demonstrates that the macrophage-inspired nanovesicle system constitutes a potent and targeted combinatorial therapy for post-infarction inflammation and repair.
- Open Access
- 20 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0345110
Intestinal barrier damage is associated with fine particulate matter (PM2.5)-induced pathological aortic injury in mice
Chronic exposure to air pollution is associated with an increased cardiovascular disease (CVD) risk, and inflammation induced by fine particulate matter (PM 2.5 ) exposure is a key driver in CVD development. However, the mechanism by which PM 2.5 causes cardiacovescular damage remains unclear. Here, Balb/c mice were intratracheally instilled with PM 2.5 suspension at doses of 2.0 mg/kg or 4.0 mg/kg body weight for 7 consecutive days to establish an aortic injury model. Pathological changes were assessed by hematoxylin and eosin (H&E), elastic Van Gieson, and Masson’s trichrome staining. Potential pathways were identified through GeneCards database analysis, R language, and Metascape pathway enrichment analysis. Immune cell profiles in the blood were analyzed by flow cytometry, and serum inflammatory cytokines were measured by enzyme-linked immunosorbent assay. Confocal microscopy was used to evaluate inflammatory cell infiltration in the aorta. Intestinal barrier integrity was assessed by transmission electron microscopy; H&E, and immunofluorescence staining; and western blotting. We found that high-dose PM 2.5 exposure led to inflammatory cell infiltration, disorganization of elastic fiber layers, and aortic tissue fibrosis. Pathway enrichment analyses indicated the involvement of pathways related to the regulation of inflammatory responses and responses to bacterial molecules. Increased inflammatory cells and pro-inflammatory cytokines were detected in the blood, accompanied by an increase in circulating lipopolysaccharide. PM 2.5 exposure disrupted the intestinal mucosal barrier, leading to reduced claudin-1 and occludin (tight junction protein) expression, which exacerbated systemic inflammation and induced aortic injury. In conclusion, PM 2.5 exposure caused pathological aortic damage and exacerbated systemic inflammation, potentially mediated by compromised intestinal barrier integrity.
- 20 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0345110
Open AccessIntestinal barrier damage is associated with fine particulate matter (PM2.5)-induced pathological aortic injury in mice
Chronic exposure to air pollution is associated with an increased cardiovascular disease (CVD) risk, and inflammation induced by fine particulate matter (PM 2.5 ) exposure is a key driver in CVD development. However, the mechanism by which PM 2.5 causes cardiacovescular damage remains unclear. Here, Balb/c mice were intratracheally instilled with PM 2.5 suspension at doses of 2.0 mg/kg or 4.0 mg/kg body weight for 7 consecutive days to establish an aortic injury model. Pathological changes were assessed by hematoxylin and eosin (H&E), elastic Van Gieson, and Masson’s trichrome staining. Potential pathways were identified through GeneCards database analysis, R language, and Metascape pathway enrichment analysis. Immune cell profiles in the blood were analyzed by flow cytometry, and serum inflammatory cytokines were measured by enzyme-linked immunosorbent assay. Confocal microscopy was used to evaluate inflammatory cell infiltration in the aorta. Intestinal barrier integrity was assessed by transmission electron microscopy; H&E, and immunofluorescence staining; and western blotting. We found that high-dose PM 2.5 exposure led to inflammatory cell infiltration, disorganization of elastic fiber layers, and aortic tissue fibrosis. Pathway enrichment analyses indicated the involvement of pathways related to the regulation of inflammatory responses and responses to bacterial molecules. Increased inflammatory cells and pro-inflammatory cytokines were detected in the blood, accompanied by an increase in circulating lipopolysaccharide. PM 2.5 exposure disrupted the intestinal mucosal barrier, leading to reduced claudin-1 and occludin (tight junction protein) expression, which exacerbated systemic inflammation and induced aortic injury. In conclusion, PM 2.5 exposure caused pathological aortic damage and exacerbated systemic inflammation, potentially mediated by compromised intestinal barrier integrity.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 15531-15547
Engineered Hybrid Nanovesicles Combining Macrophage Membranes and Artificial Lipids for Abdominal Aortic Aneurysm Therapy
Background and Aims: Abdominal aortic aneurysm (AAA) is a vascular condition with high mortality for which no pharmacological treatments have been approved. Targeting endothelial dysfunction as a primary disease initiator, the vascular endothelial cell (VEC)- protective compound Senkyunolide I (SEI) demonstrates therapeutic promise through robust antiapoptotic activity. Nevertheless, SEI’s clinical translation faces limitations due to systemic toxicity, necessitating development of safer therapeutic alternatives. Results: This study presents an engineered biomimetic nanoplatform (Lipo-MM nanoparticles) combining macrophage-derived membranes with synthetic lipid bilayers for targeted SEI delivery. The macrophage membrane component facilitates precise targeting of activated VECs, while optimized artificial membrane fluidity enhances nanoparticle stability. This dual-membrane configuration enables sustained SEI release with enhanced biodistribution, achieving superior cytoprotective effects. Notably, we established a novel fusion membrane delivery system (Lipo-MM/SEI) and validated its therapeutic efficacy in angiotensin II-challenged AAA murine models. The nanocarrier significantly attenuated AAA progression, reflected by decreased 40% of AAA incidence, 31.4% of maximum aortic diameter, reduced elastin degradation and prevented fatal rupture events. Furthermore, Lipo-MM/SEI administration substantially reduced hepatorenal toxicity associated with free SEI administration during chronic treatment. Conclusion: These results demonstrate that hybrid biomimetic systems integrating natural cellular components with engineered materials offer a strategic approach for vascular endothelial repair therapy while minimizing off-target effects. This membrane fusion technology establishes a prototype for developing next-generation targeted vascular therapeutics.
- 1 December 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 15531-15547
Open AccessEngineered Hybrid Nanovesicles Combining Macrophage Membranes and Artificial Lipids for Abdominal Aortic Aneurysm Therapy
Background and Aims: Abdominal aortic aneurysm (AAA) is a vascular condition with high mortality for which no pharmacological treatments have been approved. Targeting endothelial dysfunction as a primary disease initiator, the vascular endothelial cell (VEC)- protective compound Senkyunolide I (SEI) demonstrates therapeutic promise through robust antiapoptotic activity. Nevertheless, SEI’s clinical translation faces limitations due to systemic toxicity, necessitating development of safer therapeutic alternatives. Results: This study presents an engineered biomimetic nanoplatform (Lipo-MM nanoparticles) combining macrophage-derived membranes with synthetic lipid bilayers for targeted SEI delivery. The macrophage membrane component facilitates precise targeting of activated VECs, while optimized artificial membrane fluidity enhances nanoparticle stability. This dual-membrane configuration enables sustained SEI release with enhanced biodistribution, achieving superior cytoprotective effects. Notably, we established a novel fusion membrane delivery system (Lipo-MM/SEI) and validated its therapeutic efficacy in angiotensin II-challenged AAA murine models. The nanocarrier significantly attenuated AAA progression, reflected by decreased 40% of AAA incidence, 31.4% of maximum aortic diameter, reduced elastin degradation and prevented fatal rupture events. Furthermore, Lipo-MM/SEI administration substantially reduced hepatorenal toxicity associated with free SEI administration during chronic treatment. Conclusion: These results demonstrate that hybrid biomimetic systems integrating natural cellular components with engineered materials offer a strategic approach for vascular endothelial repair therapy while minimizing off-target effects. This membrane fusion technology establishes a prototype for developing next-generation targeted vascular therapeutics.
- Open Access
- 26 September 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 155, 113749
The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression
- 26 September 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 155, 113749
Open AccessThe berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression
- Open Access
- 9 January 2019
- Published by MDPI AG in Marine Drugs
- Vol. 17 (1) , 38
Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice
Asperlin is a marine-derived, natural product with antifungal, anti-inflammatory and anti-atherosclerotic activities. In the present study, we showed that asperlin effectively prevented the development of obesity in high-fat diet (HFD)-fed mice. Oral administration of asperlin for 12 weeks significantly suppressed HFD-induced body weight gain and fat deposition without inhibiting food intake. Hyperlipidemia and liver steatosis were also substantially ameliorated. A respiratory metabolism monitor showed that asperlin efficiently increased energy expenditure and enhanced thermogenic gene expression in adipose tissue. Accordingly, asperlin-treated mice showed higher body temperature and were more tolerant of cold stress. Meanwhile, asperlin also increased the diversity and shifted the structure of gut microbiota. Oral administration of asperlin markedly increased the relative abundance of Bacteroidetes, leading to a higher Bacteroidetes-to-Fimicutes ratio. The HFD-induced abnormalities at both phylum and genus levels were all remarkably recovered by asperlin. These results demonstrated that asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota. Its anti-obesity properties may be attributed to its effect on promoting energy expenditure.
- 9 January 2019
- Published by MDPI AG in Marine Drugs
- Vol. 17 (1) , 38
Open AccessAsperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice
Asperlin is a marine-derived, natural product with antifungal, anti-inflammatory and anti-atherosclerotic activities. In the present study, we showed that asperlin effectively prevented the development of obesity in high-fat diet (HFD)-fed mice. Oral administration of asperlin for 12 weeks significantly suppressed HFD-induced body weight gain and fat deposition without inhibiting food intake. Hyperlipidemia and liver steatosis were also substantially ameliorated. A respiratory metabolism monitor showed that asperlin efficiently increased energy expenditure and enhanced thermogenic gene expression in adipose tissue. Accordingly, asperlin-treated mice showed higher body temperature and were more tolerant of cold stress. Meanwhile, asperlin also increased the diversity and shifted the structure of gut microbiota. Oral administration of asperlin markedly increased the relative abundance of Bacteroidetes, leading to a higher Bacteroidetes-to-Fimicutes ratio. The HFD-induced abnormalities at both phylum and genus levels were all remarkably recovered by asperlin. These results demonstrated that asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota. Its anti-obesity properties may be attributed to its effect on promoting energy expenditure.